# A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Source: https://onco.cc/trials/nct06598371/  
OnCo record `nct06598371` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of KSQ-004EX run by M.D. Anderson Cancer Center, now recruiting.

## Summary

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06598371 by M.D. Anderson Cancer Center, with 141 participants planned, started 2024-11-21, primary completion expected 2039-08-01. Conditions recorded: Select Advanced Solid Tumors. Interventions recorded: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06598371
- Phase: 1/2
- Setting: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 141

## Sources

- ClinicalTrials.gov NCT06598371: https://clinicaltrials.gov/study/NCT06598371

## Connected records

- drugs: [KSQ-004EX](https://onco.cc/drugs/ksq-004ex/)
- companies: [KSQ Therapeutics](https://onco.cc/companies/ksq-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06598371.json